Cryoport Q1 revenue $47.8M (+16% YoY); raises FY2026 guidance to $192-196M

Cryoport, Inc.

2026-Q1 EPS reported -$0.25 revenue$47,798,000

Q1 revenue $47.8M (+16% YoY); commercial CGT revenue $9.1M (+26%).
Life Sciences Services revenue $26.9M (+18%); BioStorage/BioServices up 21%.
Supported 766 global clinical trials (91 Phase 3) and 21 commercial CGTs as of March 31.
FY2026 revenue guidance raised to $192M-$196M versus prior outlook.
Four BLA/MAA filings in Q1; Rocket Pharma FDA approval for KRESLADI gene therapy.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Cryoport, Inc. reported first quarter (Q1) of 2026 results: revenue $47.8 million. Guidance raised.

Period: first quarter (Q1) of 2026
Revenue: $47.8 million
Guidance: raised
Result: reported results

Exact text from the filing

99.1) --- EX-99.1 2 tm2613494d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports First Quarter 2026 Financial Results ● First quarter revenue grew 16% year-over-year to $47.8 million ● Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs ● Life Sciences Services

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Cryoport, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-054942

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.